No profile data available.
Viatris Inc. (VTRS) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Canonsburg, United States, with about 30,000 full-time employees.
It reported revenue of $14.30 billion for fiscal year 2025, down 3.0% from fiscal year 2024, and net income of -$3.51 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $3.76 billion, up 4.9% from a year before. Its largest business segment, Developed Markets, brought in 60% of segment revenue in fiscal year 2025. Its market capitalization was $20.26 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Viatris reported $14.30 billion in revenue for fiscal year 2025, down 3.0% from $14.74 billion in fiscal year 2024. In Q2 2026 revenue was $3.76 billion.
Developed Markets, with $8.55 billion or 60% of segment revenue in fiscal year 2025. Next: Greater China (16%) and Emerging Markets (16%).
$20.26 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Teva Pharmaceutical Industries Limited (TEVA), Haleon plc (HLN), Royalty Pharma plc (RPRX), Dr. Reddy's Laboratories Limited (RDY).